NEFL and Alzheimer disease: The present study examined whether plasma markers of AD pathology (Aβ42/40, pTau-181), astrogliosis (GFAP), and neuronal injury (NfL) predict longitudinal changes in brain volume and cognitive performance in a sample of cognitively unimpaired adults over a median follow-up of five to six years.